Improved protection in guinea pigs after vaccination with a recombinant BCG expressing MPT64 on its surface

Simon O. Clark, Giovanni Delogu, Emma Rayner, Michela Sali, Ann Williams, Riccardo Manganelli

Research output: Contribution to journalArticle

Abstract

The lack of an efficient vaccine against tuberculosis is still one of the major problems threatening global human health. In previous work we showed that expression of the protective antigen MPT64 on the surface of Mycobacterium bovis BCG, the only approved vaccine against tuberculosis, strongly improved its immunogenicity and protective potential in mice. In this work we demonstrate that the same recombinant strain is able to induce better protection than wild type BCG also in guinea pigs preventing Mycobacterium tuberculosis dissemination and lung pathology, making this strain a strong candidate for further testing.

Original languageEnglish
Pages (from-to)29-32
Number of pages4
JournalTrials in Vaccinology
Volume4
DOIs
Publication statusPublished - 2015

Keywords

  • Animal model
  • Guinea pigs
  • Tuberculosis
  • Vaccines

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Improved protection in guinea pigs after vaccination with a recombinant BCG expressing MPT64 on its surface'. Together they form a unique fingerprint.

Cite this